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Summary
Treatment-resistant depression is a severely disabling
disorder with no proven treatment options once mul-
tiple medications, psychotherapy, and electroconvul-
sive therapy have failed. Based on our preliminary
observation that the subgenual cingulate region (Brod-
mann area 25) is metabolically overactive in treatment-
resistant depression, we studied whether the applica-
tion of chronic deep brain stimulation to modulate
BA25 could reduce this elevated activity and produce
clinical benefit in six patients with refractory depres-
sion. Chronic stimulation of white matter tracts adja-
cent to the subgenual cingulate gyrus was associated
with a striking and sustained remission of depression
in four of six patients. Antidepressant effects were
associated with a marked reduction in local cerebral
blood flow as well as changes in downstream limbic
and cortical sites, measured using positron emission
tomography. These results suggest that disrupting fo-
cal pathological activity in limbic-cortical circuits us-*Correspondence: hmayber@emory.edu (H.S.M.); lozano@uhnres.
utoronto.ca (A.M.L.)ing electrical stimulation of the subgenual cingulate
white matter can effectively reverse symptoms in
otherwise treatment-resistant depression.
Introduction
Major depression is the most common of all psychiatric
disorders (Wang, 2003). It ranks among the top causes
of worldwide disease burden and is the leading source
of disability in adults in North America under the age of
50 (World Health Organization, 2001). While depression
can be effectively treated in the majority of patients by
either medication or some form of evidence-based psy-
chotherapy (American Psychiatric Association, 2000),
up to 20% of patients fail to respond to standard inter-
ventions (Fava, 2003; Keller et al., 1992). For these pa-
tients, trial-and-error combinations of multiple medic-
ations and electroconvulsive therapy are often required
(Kennedy and Lam, 2003; Lancet UK ECT Review
Group, 2003; Sackeim et al., 2001). For patients who
remain severely depressed despite these aggressive
approaches, new strategies are needed. We describe a
strategy directed at this group of treatment-refractory
patients with major depression.
Converging clinical, biochemical, neuroimaging, and
postmortem evidence suggests that depression is un-
likely to be a disease of a single brain region or neuro-
transmitter system. Rather, it is now generally viewed
as a systems-level disorder affecting integrated path-
ways linking select cortical, subcortical, and limbic
sites and their related neurotransmitter and molecular
mediators (Manji et al., 2001; Mayberg, 1997; Nemeroff
2002; Nestler et al., 2002; Vaidya and Duman, 2001).
While mechanisms driving this “system dysfunction”
are not yet characterized, they are likely to be multifac-
torial, with genetic vulnerability, developmental insults,
and environmental stressors all considered important
and synergistic contributors (Caspi et al., 2003; Heim
et al., 2000; Kendler et al., 2001). Treatments for depres-
sion can be similarly viewed within this limbic-cortical
system framework, where different modes of treatment
modulate specific regional targets, resulting in a variety
of complementary, adaptive chemical and molecular
changes that re-establish a normal mood state (Vaidya
and Duman 2001; Hyman and Nestler, 1996, Mayberg
2003).
Functional neuroimaging studies have had a critical
role in characterizing these limbic-cortical pathways
(Brody, et al., 2001; Drevets, 1999; Mayberg, 1994,
2003). Our own studies have demonstrated consistent
involvement of the subgenual cingulate (Cg25) in both
acute sadness and antidepressant treatment effects,
suggesting a critical role for this region in modulating
negative mood states (Mayberg et al., 1999; Semino-
wicz et al., 2004). In support of this hypothesis, a de-
crease in Cg25 activity is reported with clinical re-
sponse to different antidepressant treatments including
specific serotonin reuptake inhibitor (SSRI) antidepres-
sant medications, electroconvulsive therapy (ECT), re-
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652petitive transcranial magnetic stimulation (rTMS), and 1
uablative surgery (Dougherty et al., 2003; Goldapple et
al., 2004; Malizia, 1997; Mayberg et al., 2000; Mottaghy t
tet al., 2002; Nobler et al., 2001).
In addition, Cg25 connections to the brainstem, hy- a
rpothalamus, and insula have been implicated in the
disturbances of circadian regulation associated with t
sdepression (sleep, appetite, libido, neuroendocrine
changes) (Barbas et al., 2003; Freedman et al., 2000; p
wJurgens and Muller-Preuss, 1977; Maclean, 1990; On-
gur et al., 1998). Reciprocal pathways linking Cg25 to e
Vorbitofrontal, medial prefrontal, and various parts of the
anterior and posterior cingulate cortices form the neu- 3
iroanatomical substrates by which primary autonomic
and homeostatic processes influence various aspects t
cof learning, memory, motivation and reward—core be-
haviors altered in depressed patients (Barbas et al.,
i2003; Carmichael and Price, 1996; Haber, 2003; Vogt
and Pandya, 1987). a
iRecent advances in the surgical treatment of Parkin-
son’s disease have demonstrated that chronic high-fre- b
squency deep brain stimulation (DBS) in pathologically
overactive brain circuits produces profound clinical i
rbenefits (Benabid, 2003; Lang and Lozano, 1998). We
have previously shown that clinically effective DBS in w
athe basal ganglia produces both local and remote
changes in neural activity as assessed by positron s
Iemission tomography (PET) (Davis et al., 1997). We
have now leveraged these observations to investigate n
Iwhether DBS could be used to modulate pathological
brain circuits in depression. f
1We tested the hypothesis that the use of chronic
stimulation to modulate Cg25 gray matter and intercon- o
onected frontal and subcortical regions could reverse
the pathological metabolic activity in these circuits and d
pproduce clinical benefits in patients with treatment-
resistant depression (TRD). This study reports the use i
hof high-frequency subgenual cingulate white matter
(Cg25WM) DBS in six TRD patients. s
Results P
S
Patients P
All six patients met DSM IV-TR criteria for major de- t
pressive disorder (MDD) with a major depressive epi- w
sode (MDE) of at least 1 year duration diagnosed by 1
structured clinical interview for DSM IV-TR (First et al., a
2001), and all had severe depression with a minimum s
score at entry of 20 on the 17 item Hamilton Depression s
Rating Scale (HDRS) (Hamilton, 1960). Each met strin- i
gent criteria for treatment resistance defined as failure t
to response to a minimum of four different antide- (
pressant treatments, including medications, evidence- p
based psychotherapy, or electroconvulsive therapy, g
administered at adequate doses and duration during b
the current episode (Fava, 2003; Sackeim et al., 2001; t
Thase and Rush 1997). Subjects’ demographic charac- m
teristics are presented in Table 1. n
t
cIntraoperative Findings
DBS electrodes were implanted in Cg25WM under local e
anesthesia using MR imaging guidance (Figure 1, row
1: A/B and row 2: C/D) (Schaltenbrand and Wahren, t977). A protocol similar to that used in evaluating stim-
lation thresholds for efficacy or adverse effects in pa-
ients with Parkinson’s disease was adopted for use in
hese patients (Benabid, 2003; Davis et al., 1997; Lang
nd Lozano, 1998). The spontaneous report or occur-
ence of any acute behavioral, cognitive, motor, or au-
onomic effects was sought during blinded, sequential
timulation of successive, individual contacts (mono-
olar stimulation, 60 µs pulsewidths, 130 Hz). Voltage
as progressively increased up to 9.0 V at each of the
ight electrode contacts (four per side), as tolerated.
oltage was increased by approximately 1.0 V every
0 s, with a 15–20 s pause between adjustments, allow-
ng time for patients to identify an effect, if present. Pa-
ients reported no motor or sensory phenomena that
ued them as to whether current was either on or off.
All patients spontaneously reported acute effects
ncluding “sudden calmness or lightness,” “disappear-
nce of the void,” sense of heightened awareness,
ncreased interest, “connectedness,” and sudden
rightening of the room, including a description of the
harpening of visual details and intensification of colors
n response to electrical stimulation. Reproducible and
eversible changes in these phenomena, time locked
ith stimulation, were observed at specific contacts
nd parameters for individual patients and not with
ham or subthreshold stimulation at those same sites.
ncreases in motor speed, volume, and rate of sponta-
eous speech and improved prosody were observed.
n addition, changes in both positive and negative af-
ective rating scores (PANAS scale) (Watson and Clark,
988) occurred coincident with the patients’ spontane-
us statements. There were no overt adverse affective
r autonomic changes with stimulation at settings pro-
ucing these improvements. However, all patients ex-
erienced stimulation dose-dependent adverse effects
ncluding lightheadedness and psychomotor slowing at
igh settings (over 7.0 Volts), most often seen at the
uperior electrode contact.
ostoperative Findings: Short-Term
timulation Effects
ostoperative MR imaging confirmed the placement of
he DBS electrodes within the subgenual cingulate
hite matter (Cg25WM) bilaterally as targeted. (Figure
, row 3: E/F). During the 5 day postoperative period,
nd prior to placement of the pulse generator, daily
hort sessions of DBS were used to refine final contact
election and stimulation parameters. Systematic test-
ng of individual and paired unilateral and bilateral con-
acts was performed with a variety of parameters
monopolar [contact anode; case cathode] and bipolar,
ulsewidth of 30–250 s, frequency of 10–130 Hz, pro-
ressive increase in voltage from 0.0–9.0 Volts). Acute
ehavioral changes were again observed during these
est sessions. Reproducible improvements in interest,
otor speed, activity level, and PANAS scores (reduced
egative, increased positive scores) were seen during
hese stimulation sessions generally using the same
ontacts and parameters that induced effects in the op-
rating room.
To control for the possibility of a placebo effect, pa-
ients were blinded as to which contact was being stim-
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653Table 1. Patient Demographics
Patient # 1 2 3 4 5 6 Group
Gender F M F M M F 3F/3M
Current age 48 59 45 48 37 39 46 ± 8
Age MDD onset 18 45 21 40 19 34 29.5 ± 12
Current episode (yrs) 1.5 3 6 8 10 5 5.6 ± 3
# Lifetime episodes 12 9 3 1 2 1 4.7 ± 5
Hamilton depression score 29 20 27 24 26 25 25 ± 3
(17 item)
Past ECT no yes yes yes yes yes 5 of 6
Past psychotherapy yes yes yes yes yes yes 6 of 6
Family history MDD yes no yes yes yes yes 5 of 6
DSM IV diagnosis UP BPII UP UP UP UP 5 UP
Melancholic subtype yes no yes no yes yes 4 of 6
Current medicationsa 1–5 1, 3 1–4 1, 2, 4, 6, 7 1, 7 1, 4, 5, 7
MDD, major depressive disorder; ECT, electroconvulsive therapy; DSM IV, Diagnostic and Statistical Manual of Mental Disorders, Version IV;
UP, unipolar; BP, bipolar.
a Current medications: 1, SSRI/SNRI; 2, bupropion; 3, atypical antipsychotic; 4, benzodiazepine; 5, stimulant; 6, mood stabilizer; 7, other.and correspondingly longer carry-over of the beneficial
Figure 1. DBS Electrode Placement in the Subgenual Cingulate
White Matter
(Row 1) Sagittal (left, [A]) and coronal (right, [B]) views of the sub-
genual cingulate target (white circles) localized on the Schalten-
brandt neurosurgical atlas. (Row 2) Sagittal (C) and coronal (D)
views of the DBS target mapped on a high-resolution T1 MRI scans
for one patient. (Row 3) Sagittal (E) and coronal (F) views of postop
MRI scans demonstrating the location of electrodes for a single
subject with the ventral contact centered within the predetermined
location. sgCg, subgenual cingulate; cc, corpus callosum; g, genu
of the corpus callosum; ac, anterior commissure; white circles,
electrode target in sgCg white matter; white and black arrows,
sgCg gyrus; dotted line, anterior-posterior position of the electrode
relative to the ac-g line.ulated and to the parameter settings. Sham stimulation
using either 0.0 Volts or subthreshold stimulation failed
to elicit any changes in behavior. Randomized, acute
off-on-off-on trials of varying short periods of stimula-
tion (1–5 min) at optimal settings produced consistent
stimulation-locked behavioral improvements. Unexpect-
edly, with application of stimulation for progressively
longer periods (from 1 to 3 hr), there was an increasingbehavioral effects beyond cessation of the stimulation.
These longer stimulation periods were free of adverse
effects and were the basis for selecting the stimulation
settings used chronically.
Postoperative Selection of Stimulation Parameters
Patients were discharged home with stimulation “off”
following implantation of the pulse generators. One
week later, chronic DBS was initiated using the lowest
voltage and specific electrode contacts that had pre-
viously produced acute behavioral effects. Parameters
of stimulation were reassessed at weekly intervals with
minor adjustments in voltage made to optimize clinical
effects. Following a 4 week period of parameter optimi-
zation, settings generally remained stable for the re-
mainder of the 6 month follow-up period. The mean
stimulation parameters used in this group at 6 months
were 4.0 Volts, 60 µs pulsewidths, at a frequency of
130 Hz.
Efficacy of Chronic Bilateral Cg25WM DBS
Standard criteria for antidepressant response and re-
mission were applied (Frank et al., 1991). Response
was defined as a decrease in the HDRS-17 score of
50% or greater from the pretreatment baseline; re-
mission as an absolute HDRS-17 score <8. One month
postop, two patients met criteria for clinical response
(Table 2). By 2 months, five of the six patients met the
defined response threshold. Continued antidepressant
response was seen in four of these subjects, with some
variability up to 5 months. At the 6 month study end-
point, antidepressant response was maintained in four
subjects (66%). Moreover, three of these subjects
achieved remission or near remission of illness. Consis-
tent with the improvements seen in the HDRS-17
scores, comparable changes were also demonstrated
on other quantitative depression scales (see Table 3).
Presurgical medications and doses were unchanged
throughout the 6 month study.
Normalization of early-morning sleep disturbance
(middle insomnia commonly seen in MDD) occurred in
the first week of chronic DBS in four of the six subjects
(patients 1, 3, 5, and 6) and was the first notable sus-
Neuron
654Table 2. Hamilton Depression Rating Scale, HDRS-17, Scores over Time for Each Subject
Hamilton ScoreaTime
Pt 1b Pt 2c Pt 3b Pt 4c Pt 5b Pt 6b
Preop baseline 29 22 29 24 26 25
1 week postop (acute stimulation) 5 10 12 18 17 12
2 weeks postop (DBS off) 9 13 23 18 22 n/a
1 month 10 14 17 20 22 12
2 months 13 11 12 18 10 12
3 months 2 15 14 25 7 14
4 months 4 9 12 24 6 12
5 months 5 18 7 23 8 n/a
6 months 5 15 9 23 6 12
a Clinical response: decrease HDRS score >50%. Clinical remission: absolute HDRS score <8.
b Clinical responders.
c Clinical nonresponders.ments seen in the other four subjects. DBS). This remission was sustained at 6 weeks of resu-
Table 3. Psychiatric Ratings: Patient Subgroups
All Patients Responders Nonresponders
(n = 6) Mean Scores (SD) (n = 4) Mean Scores (Range) (n = 2) Mean Scores (Range)
Preop 1 mo 3 mo 6 mo Preop 1 mo 3 mo 6 mo Preop 1 mo 3 mo 6 mo
HDRS 17 25.8 15.8 12.8 11.5 27.3 15.3 9.3 7.8 23 17 20 19
(2.8) (4.7) (7.8) (6.8) (2.1) (5.4) (5.9) (3.1) (22–24) (14–20) (15–25) (15–23)
HDRS 24 34.6 25.8 21.2 18.8 35.7 25 15.3 11.3 33 27 30 30
(1.9) (9.1) (8.7) (10.6) (1.5) (12.5) (3.5) (2.9) (32–34) (24–30) (27–33) (27–33)
MADRS 33.3 23 17.4 18.5 33.8 20.7 11 9.7 33 27 27 29
(4.5) (8.5) (10.1) (10.4) (6.7) (11.1) (3.6) (3.8) (31–34) (25–28) (21–33) (25–33)
CGI 6.2 5.2 4.2 4.0 6.3 4.7 3.3 3.0 6 6 6 6
(0.4) (0.8) (0.6) (1.7) (0.5) (0.6) (1.0) (0.8) (6) (6) (6) (6)
Note: f/u MADRAS and HDRS 24 scores not available for patient 6.tained symptom change. Over the initial few weeks of C
Wcontinuous DBS, increased energy, interest, and
psychomotor speed were additionally reported, with ef- r
ffects generally appreciable a day or two following stim-
ulation adjustments. Patients and their families de- c
sscribed renewed interest and pleasure in social and
family activities, decreased apathy and anhedonia, as i
awell as an improved ability to plan, initiate, and com-
plete tasks that were reported as impossible to attempt i
(prior to surgery. While all patients continued to report
feeling “moderately depressed” for several weeks, sev- m
seral also indicated that the sensations of “painful emp-
tiness” and “void” remitted almost immediately follow- s
ping onset of stimulation at the optimal contacts.
Two patients failed to show a sustained antidepres- s
tsant response at the 6 month time point (Table 2). One
of these subjects, patient 2, met criteria for clinical re- t
hsponse in the first 4 months; however, the level of im-
provement fluctuated over time, and the maximal bene- i
ffit could not be recaptured with either a change in the
stimulation contact or adjustments in stimulation w
(parameters after 4 months. Patient 4 had no apprecia-
ble clinical improvement with chronic stimulation de- b
tspite trials with various combinations of contacts and
stimulation parameters. Of note, the prominent sleep T
pdisturbances in these two patients (difficulty falling
asleep [patient 4] and hypersomnia [patient 2]) were not a
5affected by DBS, unlike the middle insomnia improve-ontrol Condition: Blinded DBS Discontinuation
e next considered that the long-term benefit in the
esponders could be related to placebo or nonspecific
actors. To examine this possibility, after a period of
ontinuous stimulation for 6 months, the effects of ces-
ation and reintroduction of stimulation was examined
n patient 1, who had shown the earliest, most robust,
nd best-sustained clinical response (Table 2). Follow-
ng blinded discontinuation of bilateral stimulation
stimulators set at 0.0 V), antidepressant effects were
aintained for 2 weeks (HDRS = 9; PANAS positive
core = 48 of out of a possible 50, PANAS negative
core = 10 out of a possible 50 versus 6 month score
ositive = 50, negative = 10). In weeks 3 and 4 without
timulation, the improvements in mood were also sus-
ained (HDRS = 10). In the context of this sustained eu-
hymia, however, there was a progressive change in be-
avior characterized by loss of energy and initiative,
mpaired concentration, and reduced activities, re-
lected by a drop in the PANAS positive score to 37,
ithout appreciable change in the negative score
negative = 13). At this point, and under continued
linded conditions, the stimulator was turned back on
o the previous best settings (3.5 V, PW 60, 130 Hz).
his resulted in normalization of symptoms within ap-
roximately 48 hr and return to prediscontinuation
ctivities within 1 week (HDRS = 6, PANAS positive =
0, negative = 10 after 1 week of restarting chronic
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655med stimulation at comparable levels to the prediscon-
tinuation baseline (HDRS = 4). Taken together, these
findings suggest that stimulation of Cg25WM produces
long-term improvements in mood that are sustained
beyond the period of active stimulation. The cognitive
aspects of depression (i.e., poor concentration, apathy)
also show sustained improvements, but the observed
changes appear to have a different biology and kinet-
ics, decaying closer to the cessation of stimulation.
PET Measures of Regional Blood Flow:
Baseline and Treatment Effects
Positron emission tomography was used to character-
ize the activity in brain networks involved in TRD and
to provide a quantitative measure of brain changes as-
sociated with stimulation. Baseline, resting-state, cere-
bral blood flow (CBF) PET scans were performed in the
first five study subjects and compared to five age- and
sex-matched, nondepressed healthy volunteers. De-
pressed patients showed a unique pattern of elevated
subgenual cingulate (Cg25) blood flow at pretreatment
baseline, not previously reported in studies of non-
treatment resistant patients. In addition, and consistent
with past studies of depressed patients (reviewed in
Mayberg, 2003), CBF decreases in prefrontal (BA9/46),
premotor (BA6), dorsal anterior cingulate (BA24), and
anterior insula were also identified (Figure 2 row 1; Ta-Figure 2. PET Scans
Regional cerebral blood flow changes (CBF PET) in TRD patients
at baseline (row 1) and after 3 months (row 2) and 6 months (row
3) of successful treatment with continuous DBS. Sagittal (left) and
coronal (right) views. Baseline CBF abnormalities are seen relative
to age- and gender-matched healthy control subjects (NC): in-
creases in subgenual cingulate (Cg25) and decrease in dorsolateral
prefrontal (F9), ventrolateral prefrontal (F47) and anterior cingulate
(Cg24) cortices (row 1, patients 1–5). Three months of DBS relative
to baseline (row 2, patients 1, 3, and 5): decreases in Cg25, hypo-
thalamus (Hth), anterior insula (ins), medial frontal (mF10) and or-
bital frontal (oF11); increases in prefrontal (F9/46) and dorsal cingu-
late (cg24). This same pattern is maintained at 6 months, although
additional increases are seen in the brainstem (bs) (row 3). Slice
location is in millimeters relative to anterior commissure. Numbers
are Brodmann designations. L, left. Significant CBF increases in
red; decreases in blue (p < 0.001).ble 4, left). A similar pattern of hyperactive Cg25 and
hypoactive prefrontal cortex was seen in both the DBS
responders and nonresponders (data not shown). Re-
sponder versus nonresponder differences at baseline
were seen primarily in the magnitude of the prefrontal
decreases (responders > nonresponders). Responders
also showed an area of hyperactivity in the medial fron-
tal cortex (BA10) not seen in the nonresponders; how-
ever, the small sample size precluded further analysis.
The time course of CBF changes with chronic stimu-
lation of Cg25WM was also examined to establish the
relationship of regional brain functioning to behavioral
effects. Serial scans were performed after 3 and 6
months in four of the first five patients (1, 2, 3, and
5). Group analyses showed local CBF decreases in
Cg25 and adjacent orbital frontal cortex (BA11) after 3
months of stimulation. The long-term responders (pa-
tients 1, 3, and 5) showed additional CBF changes at
both 3 and 6 months: decreases in hypothalamus, ante-
rior insula, and medial frontal cortex (BA10) as well as
increases in dorsolateral prefrontal (BA9/46), dorsal an-
terior (BA24) and posterior cingulate (BA31), premotor
(BA6), and parietal (BA40) regions (Table 4; Figure 2,
rows 2 and 3). Neither the medial frontal (BA10) de-
creases nor the dorsal prefrontal (BA9/46), anterior cin-
gulate (BA24), or parietal (BA40) increases were seen in
the nonresponder (patient 2) at either 3 or 6 months
(data not shown).
The stimulation-induced CBF increases in prefrontal
cortex (BA9/46) normalized pretreatment abnormalities.
Similarly, the Cg25 decreases not only normalized pre-
treatment dysfunction, but activity in this region with
DBS was actually suppressed below that of the con-
trols at both time points, a change also observed in our
previous studies of PET scan changes with response
to antidepressant medications (Mayberg et al., 2000).
Unlike medication, brainstem changes were not seen
early with DBS, although changes in the pons were
demonstrated at the 6 month time point. Overall, re-
gional changes seen after 3 months were maintained at
6 months in all three responders (Table 4, middle and
right sections).
Neuropsychological Testing
A comprehensive neuropsychological battery was per-
formed prior to surgery and after 3 and 6 months of
stimulation, coincident with the day of the PET scan
sessions. The test battery was designed to differentiate
dorsolateral, superior medial, and ventrolateral/orb-
ital frontal behaviors, potentially affected by chronic
Cg25WM DBS. Serial testing further allowed differentia-
tion between subacute surgical effects, chronic stimu-
lation effects, and correlations with mood change.
At baseline, all patients were functioning intellectu-
ally in the average range, consistent with estimates of
premorbid IQ. Inspection of results over time indicates
that surgery itself did not have a negative impact on
general cognition (i.e., IQ, language, basic visual-spa-
tial function). Moreover, many specific areas that were
below average or impaired at baseline were signifi-
cantly improved (or trending due to low power) follow-
ing 6 months of DBS [responders: visuo-motor func-
tion, particularly with the nondominant hand, t(2) = 5.8,
Neuron
656Table 4. PET Blood Flow Changes
Baselinea Patients (n = 5) 3 Months DBS vs Baselineb,c 6 Months DBS vs Baselineb,c
vs Controls (n = 5)c Responders (n = 3) Responders (n = 3)
x y z x y z x y z
z Coordi- z Coordi- z Coordi-
Region BA  Score nates Region BA  Score nates Region BA  Score nates
sgCg 25 L [ 5.16 −10 28 −12 sgCg 25 Y −4.75 −2 8 −10 sgCg 25 Y −3.88 10 20 −4
Hth Y −3.67 0 4 −12 Hth Y −4.63 −2 2 −4
OrbF 32/10 Y −5.1 0 34 −8 OrbF 32/11 L Y −4.97 −10 30 −10
32/10 R Y −4.84 6 46 2
10 R Y −3.98 22 60 −10 11/10 L Y −4.41 −20 36 −10
aIns L [ 6.05 −38 22 14 Ins R Y −3.76 60 10 −6 Ins R Y −4.07 58 16 −6
L Y −5.74 −50 16 −16 L Y −5.67 −50 20 −6
mFr 10 R [ 6.22 26 42 16 mFr 10 L Y −4.19 −22 62 22 mFr 10 L Y −3.53 −14 56 38
10 R Y −5.95 34 56 26 10 L Y −4.27 −28 56 32
24 R Y −5.86 12 22 26 24 R Y −4.19 12 20 20
24 L Y −3.79 −16 24 22
mFr 9 R Y −5.57 12 46 34 mFr 9 R Y −3.95 6 52 30
L Y −4.87 −5 56 34 9 R Y −3.34 2 46 40
Fr pole 9 L Y −5.96 −28 54 43
R Y −5.19 18 52 34
pCg 31 L [ 4.43 −8 −54 26 pCg 31 L [ 4.65 −10 −72 20
R [ 3.88 10 −56 26 31 R [ 3.51 24 −68 14
DLPF 9 L Y −7.07 −38 28 30 DLPF 9 L [ 4.05 −26 16 30 DLPF 9 R [ 4.63 38 12 34
R Y −4.92 40 20 30 46/9 L [ 3.79 −34 18 24
VLPF 47 L Y −4.66 −52 42 2 46 L [ 4.73 −38 32 18 46 R [ 4.13 32 24 10
R Y −4.98 32 26 0 46 R [ 4.91 34 22 16 46 L [ 3.84 −38 26 10
dCg 24b L Y −5.39 −2 18 28 dCg 24b L [ 4.06 −2 10 28 dCg 24b L [ 3.58 −4 4 34
PM 6 L [ 4.21 −52 −4 32 PM 6 L [ 3.34 −48 2 22
6 R [ 5.71 50 0 30 6 R [ 5.92 50 4 28
Par 39 L [ 4.13 −36 −56 18
39 R [ 4.01 44 −56 10
Caudate R Y −4.69 14 2 12 PAG R Y −4.66 6 −36 −10
aThal R Y −4.58 12 −6 14
n. acc L Y −4.68 −4 10 −4
a Patients 1–5 versus five age- and gender-matched healthy controls.
b Patients 1, 3, and 5.
c SPM t maps. Significance threshold: p < 0.001 uncorrected (t > 3.27); cluster size >50 voxels.p = 0.014; dorsolateral frontal function (verbal fluency), t
st(2) = 10.0, p = 0.005; ventral prefrontal function (fewer
errors on object alternation task), t(2) = 1.7, p = 0.12; t
and orbital frontal function (fewer risky choices on the
gambling task), t(2) = 6.3, p = 0.012]. Importantly, there D
were no acquired impairments in orbital frontal func-
tioning to indicate local DBS adverse effects (Kart- I
qsounis et al., 1991; Dalgleish et al., 2004). Nonrespond-
ers had normal performance on all tests at baseline, b
iwith the exception of slowed psychomotor speed (con-
sistent with effects of depression). Repeat testing was t
monly available for one of these subjects.
b
cAdverse Events
Patients 2 and 4 developed local infections related to d
Pthe connector cable at the chest (patient 2) or scalp
(patient 4). Both were treated with intravenous antibiot- p
dics. Because of persistent infection in the absence of
clinical benefit, the devices were explanted at approxi- n
Wmately 6 months with resolution of their infections. No
worsening of depressive symptoms was observed in t
meither subject following explantation. Patient 5 devel-
oped skin erosion over the hardware and also received c
gantibiotics. While no definitive etiology of these infec-
tions was identified, the protocol was modified after pa- t
ptient 5 to implant both the electrodes and pulse genera-or in a single surgical session, thus eliminating the
everal-day period where the electrodes remained ex-
ernalized.
iscussion
n this study, we have demonstrated that high-fre-
uency DBS of the Cg25WM can produce striking
ehavioral changes in patients with TRD. Acute behav-
oral effects were time locked to stimulation intraopera-
ively and during short-term testing sessions. Further-
ore, sustained clinical improvements decreased with
linded discontinuation of chronic DBS and were re-
aptured with reinstitution of stimulation, providing evi-
ence as to the specificity of DBS-mediated changes.
ET scan data further indicate that Cg25WM DBS has
rofound effects on the cerebral networks involved in
epression and suggest that reversal of baseline ab-
ormalities correlates with antidepressant benefits.
hile the number of subjects is small, four of six pa-
ients (66%) achieved sustained clinical response or re-
ission at the end of 6 months without changes in con-
urrent medications. This response rate is striking
iven the extreme treatment refractoriness of this pa-
ient population and the well-documented low and
oorly sustained placebo response rates of such pa-
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657tients (Fava, 2003; Keller, et al., 1992; Kennedy and
Lam, 2003; Thase and Rush, 1997; Sackeim et al.,
2001).
The identified CBF change pattern associated with
DBS-induced antidepressant effects has important sim-
ilarities to other therapies for depression. The pattern
of reduced activity in the Cg25 and hypothalamus to-
gether with prefrontal (BA9) and brainstem increases
during DBS are identical to changes reported with anti-
depressant response to medication (Mayberg et al.,
2000). On the other hand, the medial frontal (BA10)/
orbital frontal (BA11) decreases and dorsal cingulate
(BA24) increases are similar to the change pattern ob-
served with response to cognitive behavioral therapy
(Goldapple et al., 2004). The observation that the
changes with DBS seen here features both the antide-
pressant medication and the CBT- induced changes
suggests that Cg25WM DBS acts at a critical node of a
distributed mood-regulatory network involved in major
depression (Mayberg, 2003; Seminowicz et al., 2004).
The baseline pattern of subgenual cingulate hyperac-
tivity in combination with frontal hypoactivity described
here in this TRD patient group is a finding that is in
contrast to the hypoactivity reported in a more rostral
region of subgenual medial prefrontal cortex in familial
bipolar and unipolar depressed patients (Drevets et al.,
1997). This distinction suggests important differences
across subtypes of depression that are potentially rele-
vant to the pathophysiology of major depressive disor-
ders and perhaps their treatment.
Although the mechanisms of action of DBS are in-
completely understood, it is clear that stimulation pro-
duces both local and remote regional effects (Davis et
al. 1997). The behavioral and neuroimaging changes in
this study are consistent with suppression of the abnor-
mally elevated baseline Cg25 activity (Figure 2). Pos-
sible mechanisms include DBS-induced activation of
inhibitory GABA-ergic afferents and/or high frequency
stimulation induced synaptic or metabolic failure (Gab-
bott et al., 1997; Lozano et al., 2002; McIntyre et al.,
2004). The remote cortical and brainstem increases
could occur as an indirect consequence of trans-syn-
aptic effects in response to decreased activity in Cg25,
or direct anterograde or retrograde activation of WM
projections coursing through the stimulation field (Bar-
bas et al., 2003; Carmichael and Price, 1996; Haber,
2003; Freedman et al., 2000; Ongur et al., 1998; Jurgens
and Muller-Preuss, 1977; Vogt and Pandya, 1987).
In context of these putative mechanisms, the sudden
mood change seen with stimulation in the operating
room is consistent with an acute deactivation of a hy-
peractive Cg25, the region immediately adjacent to the
area of stimulation. This region has been previously
shown to mediate negative mood (increases with sad-
ness, decreases with alleviation of depressive dyspho-
ria) (Mayberg et al., 1999). Early effects of DBS on
sleep, energy and motivation also suggest changes in
activity of the hypothalamus and brainstem, regions
monosynaptically connected to Cg25 (Barbas et al.
2003; Freedman et al., 2000; Jurgens and Muller-Pre-
uss, 1977; Ongur et al., 1998). The more global changes
in functioning, i.e., resolution of the depressive syn-
drome, as well as the prolonged washout time and as-
sociated persistent benefit we have observed beyondthe cessation of stimulation, may reflect long-term
changes in neural network properties as a conse-
quence of prolonged stimulation (Carmichael and Price,
1996; Vaidya and Duman, 2001; Haber, 2003; Vogt and
Pandya, 1987). This phenomenon of ongoing benefit af-
ter DBS discontinuation has been observed in other
disorders targeting different brain circuits, including ep-
ilepsy, essential tremor, dystonia, and Parkinson’s dis-
ease (Hodaie et al. 2002, Kumar et al. 2003; Deep-Brain
Stimulation for Parkinson’s Disease Study Group, 2001;
Vidailhet et al., 2005).
Despite these encouraging results, there are limita-
tions to this first study of Cg25WM DBS for TRD. Sam-
ple size was small, follow-up was limited, and no sham
surgery or systematic placebo control arm was used.
There was also inadequate power to identify demo-
graphic, clinical, subtype, neuropsychological, or im-
aging markers that might predict response. It may be
relevant that all four responders had their first major
depressive episode (MDE) before age 35 and had pre-
dominant melancholic features whereas the two nonre-
sponders had first episodes in their 40s and had more
atypical symptoms (Table 1). Differences in electrode
targeting and placement and stimulation parameters
may have also contributed to the observed response
variance. The relative contribution of these various
factors will require testing of additional subjects. In the
future, the possible interactions between DBS and anti-
depressant medications need to be examined.
In conclusion, Cg25WM DBS appears to be effica-
cious for TRD. The treatment is titratable; there are ob-
jective imaging correlates of response effects; and the
procedure is well tolerated. This approach may repre-
sent an effective, novel intervention for severely dis-
abled patients with treatment-resistant depression.
Experimental Procedures
Patients
This pilot study included six patients with treatment-resistant major
depression, referred by mood disorder specialists (Table 1). The
clinical diagnosis of major depressive disorder, major depressive
episode (MDD-MDE) was independently confirmed by two psychia-
trists and a research coordinator using the Structured Clinical In-
terview for DSM-IV (First et al., 2001). Patients were selected for
surgery because they were resistant to all available therapeutic op-
tions. All had failed to respond to a minimum of four different
classes of antidepressant medications, prescribed at maximal tol-
erable doses. Failed treatments included SSRI, venlafaxine, bu-
propion, monoamine oxidase inhibitor, and tricyclic antidepres-
sants, as well as augmentation strategies using lithium, atypical
antipsychotics, and anticonvulsants. Five of the six patients had
received electroconvulsive therapy, and all had attempted cogni-
tive behavioral therapy without clinical improvement. Patients with
cerebrovascular risk factors or a previous stroke; documented
head trauma or neurodegenerative disorders; other Axis I psychiat-
ric diagnoses including schizophrenia, bipolar disorder, panic dis-
order, obsessive compulsive disorder, or evidence of global cogni-
tive impairment were excluded. Patients with psychotic symptoms,
current history of substance abuse, daily use of alcohol in the pre-
vious 3 months, or active suicidal ideations were also excluded.
Other exclusion criteria included age over 60, pregnancy (risk of
radiation exposure from the PET scans), general contraindications
for DBS surgery (cardiac pacemaker/defibrillator or other im-
planted devices), and inability or unwillingness to comply with
long-term follow-up. Final selection was made by consensus of the
investigator team. Additional subjects were screened but either did
Neuron
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Cclined.
s
a
Informed Consent Process p
The study protocol was reviewed and approved by three separate a
ethics committees at the University of Toronto: Toronto Western (
Hospital, Centre for Addiction and Mental Health, and Baycrest S
Centre for Geriatric Care. All potential subjects were referred by a t
psychiatrist that was not involved in the research protocol. They (
were then seen independently by two psychiatrists (V.V. and S.K.) b
for diagnostic assessment and if potentially eligible, introductory a
discussions took place. In all cases, the referring psychiatrist was a
involved in discussions of the potential benefits and the potential
risks associated with DBS. During subsequent meetings with one P
of the principal investigators (H.S.M.), a family member was invited
R
to attend and did so in all cases. Only after these discussions,
o
were interested candidates referred to the neurosurgical principle
1
investigator (A.L.), who explained the surgical procedure. Inter-
p
ested candidates were offered informed consent forms to read and
q
further discuss as needed. The average time from initial assess-
a
ment to signing consent was 6–8 weeks.
s
t
2Surgery
dThe general surgical procedure for the implantation of DBS
telectrodes has been previously described (Abosch and Lozano,
w2003). A stereotactic frame (Leksell G; Elekta, Inc., Atlanta, GA) was
(affixed to the patient’s head on the morning of surgery, and preop-
aerative MR images were obtained (Signa, 1.5 tesla; General
MElectric, Milwaukee, WI). The x, y, and z coordinates of the anterior
s(AC) and posterior commissures (PC) were determined using axial
b3D T1 MR images. To target the subgenual cingulate white matter
Ctarget, a midline T2 sagittal image was chosen, and the cingulate
gyrus below the genu of the corpus callosum was identified (Figure
p1, row 1) (Schaltenbrand and Wahren, 1977). A line was traced from
lthe most anterior aspect (genu) of the corpus callosum to the ante-
frior commissure and the midpoint was selected (Figure 1, row 2,
dleft). The T2 coronal section correspondent to the plane of this mid-
Mpoint was identified, and the coordinates of the transition between
wthe gray and white matters of area 25 were calculated (Figure 1,
arow 2, right).
oIn the operating room under local anesthesia, a burr hole was
(drilled 2 cm from the midline in front of the coronal suture. The
vunderlying dura mater was opened, and the exposed pial surface
gcoagulated. Tisseal (Immuno, Vienna, Austria) was used to prevent
tcerebrospinal fluid egress and minimize brain shift. The Leksell arc
twas attached to the head frame and set to the target coordinates.
lMicrorecordings were started 10 mm above the target using
aelectrodes made from parylene-C-insulated tungsten wires and
tplated with gold and platinum. Tip lengths ranged from 15 to 40
wm and impedances ranged from 0.2 to 1.5 M. Cell activity was
amplified (DAM 80 WPI Instruments) with a gain of 1000 and initially
filtered to 0.1–10 kHz. The signal was displayed on an oscilloscope N
Aand directed to a window discriminator (Winston Electronics) and
an audio monitor (Grass AM 8, with noise clipping circuit). In the t
npresent study, microelectrode mapping was mainly used to confirm
the anatomic location of the gray and white matters of area 25, c
gcharacterized respectively by the recording of neuronal activity and
cell sparse areas. The transition between these two regions was o
echosen as the final target for the implantation of the electrodes.
Final electrode location was confirmed by postoperative MRI (ex- w
cample, Figure 1, row 3).
DBS quadripolar electrodes (Medtronic 3387; Medtronic, Inc., p
lMinneapolis, MN) were implanted bilaterally. Each of the four
electrode contacts was tested for adverse effects and clinical ben- T
eefits. These contacts were numbered from 0 to 3 (right hemisphere)
and 4 to 7 (left hemisphere), 0 and 4 being the most ventral and 3 M
Tand 7 the most dorsal contacts. The electrodes remained external-
ized for 5–7 days for clinical testing. They were then connected to i
Aa pulse generator (Kinetra, Medtronic, Minneapolis, MN) that was
implanted in the infraclavicular region under general anesthesia. t
tProphylactic antibiotics were used for 24 hr after each of the surgi-
cal procedures. 6linical Evaluation and Follow-Up
linical efficacy was evaluated using standardized ratings by the
tudy psychiatrist blinded to the current stimulus parameters
nd/or changes. Standardized ratings included the Hamilton De-
ression Rating Scale (HDRS-17 and 24 item versions) (Frank, et
l., 1991), the Montgomery Asberg Depression Scale (MADRS)
Montgomery and Asberg, 1979), the Clinical Global Impressions
cale (CGI) (National Institute of Mental Health, 1970), and the Posi-
ive and Negative Affective Scale (PANAS) (Watson and Clark 1988)
Table 3). Ratings were performed weekly for the first 3 months and
iweekly until the study endpoint at 6 months, following baseline
ssessments at enrollment and 1 week prior to surgery. Medic-
tions were unchanged throughout the 6 month follow-up period.
ET Scanning Acquisition and Data Analysis
egional cerebral blood flow PET scans (rCBF) were acquired pre-
peratively and after 3 and 6 months of chronic DBS (Fox et al.,
984). Five CBF scans were acquired in each subject at each time
oint. A comparative scan-set (one time point only) was also ac-
uired under identical scanning conditions in a group of five age-
nd sex-matched healthy volunteers. All scans were acquired with
ubjects resting, with eyes closed and no explicit cognitive or mo-
or instructions. Scans were acquired on a GEMS/Scanditronix
048b camera (15 parallel slices; 6.5 mm center-to-center interslice
istance) using measured attenuation correction (68Ge/68Ga
ransmission scans). rCBF was measured using the bolus [15O]-
ater technique (35 mCi 15O-water dose/scan; scan duration 60 s)
Mayberg et al., 1999). Scans were spaced a minimum of 11 min
part to accommodate radioactive decay to background levels.
ood state (sadness and anxiety) was assessed at the end of each
can using a seven-point analog scale and the PANAS to verify
ehavioral stability over the course of the five scans (Watson and
lark, 1988).
Statistical analyses were performed using SPM99 (Wellcome De-
artment of Cognitive Neurology, London, UK) implemented in Mat-
ab (version 5.3, Mathworks Inc., Sherborn, MA). PET scans were
irst realigned and then spatially normalized into standard three-
imensional space relative to the anterior commissure using the
NI ICBM 152 stereotactic template within SPM99. The images
ere then corrected for differences in the whole-brain global mean,
nd smoothed using a Gaussian kernel to a final in-plane resolution
f 10 mm at full-width at half-maximum. Baseline abnormalities
patients versus controls) and changes with chronic DBS (3 months
ersus baseline, 6 months versus baseline) were assessed using
eneral linear models (peak voxel threshold p = 0.001; cluster
hreshold 50 voxels (voxel = 2 mm3) (Worsley et al., 1996). Resulting
values were lastly converted to z scores for interpretation. Brain
ocations are reported as x, y, z coordinates in MNI space with
pproximate Brodmann areas (BA) identified by mathematical
ransformation of SPM99 coordinates into Talairach space (http://
ww.mrc-cbu.cam.ac.uk/Imaging/) (Table 3).
europsychological Testing
comprehensive battery of neuropsychological tests was adminis-
ered at three time points to establish baseline intellectual and cog-
itive abilities prior to surgery/stimulation and to monitor for
hanges over time (3 months, 6 months). Tests were chosen to tap
eneral cognitive and intellectual function, as well as four domains
f frontal function (Bechara et al. 1994; Freedman et al., 1998; Lang
t al., 1999; Spreen and Strauss, 1998). Parallel versions were used
here possible to minimize effects of repetition, and scores are
orrected for effects of age, gender, and education, where appro-
riate. The following tests were administered: Wechsler Adult Intel-
igence Scale-III; North American Adult Reading Test; Trail Making
ests A and B; Boston Naming Test; Benton Judgment of Line Ori-
ntation Test; Hopkins Verbal Learning Test; Brief Visual Spatial
emory Test, Revised; Finger Tapping Test; Grooved Pegboard
est; Controlled Oral Word Association Test; Wisconsin Cart Sort-
ng Test; Stroop Color Word Test; Emotional Stroop Task; Object
lternation Test; Iowa Gambling Task; and the International Affec-
ive Picture System Ratings. A subset of tests is presented. Paired
tests were used to compare differences between the baseline and
months data to determine the probability that the actual mean
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659difference is consistent with zero. This comparison is aided by the
reduction in variance achieved by taking the differences, and thus
is a good choice for use with a small sample. A more detailed dis-
cussion of neuropsychological results will be published separately.
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